Tweet
Transpl Infect Dis. 2013 Jan 31. doi: 10.1111/tid.12054. [Epub ahead of print]
European guidelines for prevention and management of influenza in hematopoietic stem cell transplantation and leukemia patients: summary of ECIL-4 (2011), on behalf of ECIL, a joint venture of EBMT, EORTC, ICHS and ELN.
Engelhard D, Mohty B, de la Camara R, Cordonnier C, Ljungman P.
Source
Department of Pediatrics, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; School of Primary Health Care, Monash University, Melbourne, Victoria, Australia.
Abstract
Influenza may cause severe disease and mortality in leukemia patients and in hematopoietic stem cell transplantation recipients. The 4th European Conference of Infections in Leukemia (ECIL-4) has developed evidence-based guidelines for prevention and management of influenza infections in these patients. Real-time reverse-transcription polymerase chain reaction is the diagnostic test of choice, as it is the most sensitive and specific test for influenza. The risks for severe influenza and fatal outcome include lymphopenia, older age, influenza soon after transplantation or chemotherapy, steroid treatment, and lack of early antiviral therapy. Neuraminidase inhibitors (oral oseltamivir or inhalation of zanamivir) are currently the most effective therapeutic agents for influenza. Main preventive measures include annual vaccination of patients, household contacts, and hospital staff. This review summarizes ECIL-4's main recommendations.
? 2013 John Wiley & Sons A/S.
PMID:
23363310
[PubMed - as supplied by publisher]
European guidelines for prevention and management of influenza in hematopoietic stem cell transplantation and leukemia patients: summary of ECIL-4 (2011), on behalf of ECIL, a joint venture of EBMT, EORTC, ICHS and ELN.
Engelhard D, Mohty B, de la Camara R, Cordonnier C, Ljungman P.
Source
Department of Pediatrics, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; School of Primary Health Care, Monash University, Melbourne, Victoria, Australia.
Abstract
Influenza may cause severe disease and mortality in leukemia patients and in hematopoietic stem cell transplantation recipients. The 4th European Conference of Infections in Leukemia (ECIL-4) has developed evidence-based guidelines for prevention and management of influenza infections in these patients. Real-time reverse-transcription polymerase chain reaction is the diagnostic test of choice, as it is the most sensitive and specific test for influenza. The risks for severe influenza and fatal outcome include lymphopenia, older age, influenza soon after transplantation or chemotherapy, steroid treatment, and lack of early antiviral therapy. Neuraminidase inhibitors (oral oseltamivir or inhalation of zanamivir) are currently the most effective therapeutic agents for influenza. Main preventive measures include annual vaccination of patients, household contacts, and hospital staff. This review summarizes ECIL-4's main recommendations.
? 2013 John Wiley & Sons A/S.
PMID:
23363310
[PubMed - as supplied by publisher]
